Recruiting

Risankizumab

Sponsor:

AbbVie

Code:

NCT07039110

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.

Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.

Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Conditions

Plaque Psoriasis

Study ID

NCT07039110

Start date

Sep 9, 2025

Status verified date

Aug, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Mar, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
  • Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
  • Decision to treat with risankizumab is made prior to and independently of study participation.

Exclusion Criteria:

  • History of a sleep disorder diagnosis which the patient is currently being treated for.
  • Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
  • Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Study Design

Enrollment

700 participants

Anticipated

Interventions and Outcome Measures

Arms

Risankizumab

Participants will receive risankizumab as prescribed by their physician according to local label.

Primary outcome measure

  • Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 [ Time Frame: At 12 months ]

Central Contacts and Locations

Central contacts

Julieta Gonzalez Blanco

844-663-3742julieta.gonzalezblanco@abbvie.com

Locations

Dermatology Research Institute - Blackfoot Trail /ID# 276722

Recruiting

Calgary, Alberta, Canada, T2J 7E1

Rejuvenation Dermatology - Edmonton Downtown /ID# 276688

Recruiting

Edmonton, Alberta, Canada, T5J 3S9

Winnipeg Clinic /ID# 276751

Recruiting

Winnipeg, Manitoba, Canada, R3C 1T6

Wiseman Dermatology Research /ID# 276847

Recruiting

Winnipeg, Manitoba, Canada, R3M 3Z4

Cca Medical Research /ID# 276944

Recruiting

Ajax, Ontario, Canada, L1S 7K8

Quinte dermatology /ID# 277497

Recruiting

Belleville, Ontario, Canada, K8N 2S9

Lovegrove Dermatology /ID# 276797

Recruiting

London, Ontario, Canada, N6A 5R9

Lynderm Research Inc /ID# 276755

Recruiting

Markham, Ontario, Canada, L3P 1X2

Rejuvenation Dermatology Clinic Oakville /ID# 277492

Recruiting

Oakville, Ontario, Canada, L6H 6P8

JRB Research inc. /ID# 277730

Recruiting

Ottawa, Ontario, Canada, K1K 4L2

Factor Dermatology /ID# 278610

Recruiting

Ottawa, Ontario, Canada, K2A 2M3

SKiN Centre for Dermatology /ID# 277594

Recruiting

Peterborough, Ontario, Canada, K9J 5K2

Eternal Springtime Dermatology /ID# 278598

Recruiting

Thunder Bay, Ontario, Canada, P7C 4Y7

North York Research /ID# 276835

Recruiting

Toronto, Ontario, Canada, M2N 3A6

Toronto Dermatology Centre /ID# 276846

Recruiting

Toronto, Ontario, Canada, M3H 5Y8

Centre for Medical and Surgical Dermatology /ID# 278775

Recruiting

Whitby, Ontario, Canada, L1N 8M7

Dre Angelique Gagne-Henley M.D. inc. /ID# 276687

Recruiting

Saint-Jérôme, Quebec, Canada, J7Z 7E2

More Information

Sponsor

AbbVie

Last update posted

Aug 5, 2026

Last verified

Aug, 2026

Keywords

  • Plaque Psoriasis
  • Moderate to Severe Plaque Psoriasis
  • Risankizumab

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AbbVie on 2026-08-05.